Karyopharm Therapeutics Inc. (KPTI) Given Buy Rating at Jefferies Group LLC
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating reissued by research analysts at Jefferies Group LLC in a note issued to investors on Thursday. They presently have a $19.00 price objective on the stock, up from their prior price objective of $16.00. Jefferies Group LLC’s price objective would suggest a potential upside of 124.06% from the stock’s previous close.
A number of other analysts also recently issued reports on the company. BidaskClub upgraded Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday. Canaccord Genuity set a $18.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Tuesday. Zacks Investment Research lowered Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Robert W. Baird reiterated an “outperform” rating and issued a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Finally, Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Saturday, June 24th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $14.56.
Karyopharm Therapeutics (NASDAQ:KPTI) opened at 8.48 on Thursday. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63. The stock’s market capitalization is $399.56 million. The company has a 50 day moving average of $9.19 and a 200 day moving average of $10.04.
Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 71.65% and a negative net margin of 67,267.47%. The business’s quarterly revenue was down 95.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.84) earnings per share. Equities analysts expect that Karyopharm Therapeutics will post ($2.69) EPS for the current fiscal year.
WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/karyopharm-therapeutics-inc-kpti-given-buy-rating-at-jefferies-group-llc/1467992.html.
A number of hedge funds have recently added to or reduced their stakes in KPTI. Teza Capital Management LLC acquired a new stake in Karyopharm Therapeutics during the first quarter worth $169,000. Trexquant Investment LP purchased a new position in shares of Karyopharm Therapeutics during the second quarter valued at approximately $202,000. Metropolitan Life Insurance Co. NY raised its position in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares in the last quarter. American International Group Inc. raised its position in shares of Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock valued at $211,000 after buying an additional 2,836 shares in the last quarter. Finally, C WorldWide Group Holding A S raised its position in shares of Karyopharm Therapeutics by 30.2% in the first quarter. C WorldWide Group Holding A S now owns 16,928 shares of the company’s stock valued at $217,000 after buying an additional 3,928 shares in the last quarter. Institutional investors and hedge funds own 57.46% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.